Noocyada Qiimayaasha ee Qiimeeya ee Synthroid iyo Levoxyl
Juun 23, 2004, Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA) ayaa diidey Codsiyada Muwaadiniinta ee Abbott - ka ee Synthroid - ay soo xereeyeen Agoosto 2003 oo ku saabsan kuxunnaanta alaabada levottyroxine sodium. Shirkaddu waxay ku doodday in hababka lagu sawirayo midab-takoorka ay khatar ku yihiin, waxaana laga yaabaa inay macnaheedu tahay in badeecadaha kala duwan ee awoodda ay noqonayaan mid aan haboonayn.
FDA, si kastaba ha ahaatee, waxay diideen codsigan, kaas oo albaabka u furay badeecooyinka caadiga ah ee levothyroxin.
Badeecado badan ayaa sugayay baalasha iyada oo saddex shirkadood oo lagu dhawaaqay Juun 24, 2004, in ay heleen ansixinta FDA ee alaabooyinka levothyroxin, oo ay ku jiraan:
Mylan Laboratories - oo helay oggolaansho kiniinada levothyroxine sodium ee noocyo badan oo caan ah, noocyada guud ee Synthroid.
Sandoz Inc. - AB-rated (leviooksoxine) ee loo yaqaan "Synthroid iyo Levoxyl".
Shirkadda Lannett - ansixinta levothyroxine ee ay sameeyeen Jerome Stevens Pharmaceutical, Inc. (JSP), iibiyaha gaarka ah ee Lannett, oo aan udhaqmeynin Levoxyl. Xusuusin: Waxyaabaha ay sameeyeen Jerome Stevens oo ay u qaybisay Lannett, oo sidoo kale lagu iibiyey magaca "Unithroid," wuxuu ahaa levottyroxine ugu horeysay ee ay ansaxisay FDA.
Sida laga filan karo, labada shirkadood ee ugu sarreeya ee magacooda la yiraahdo levothyroxin, Abbott iyo King, waxay isku dayeen inay difaacaan alaabadooda Synthroid iyo Levoxyl oo ka soo horjeeda kuwan cusub ee tartanka qiimaha jaban.
Marka seddexda shirkadood oo dhan ay bilaabeen inay markiiba qaataan dawooyinka levothyroxine, isla markiiba, Abbott iyo King ayaa labaduba hoos u dhacay qiimaha saamiyadeed iyagoo rajeynaya wadaagidda suuqa lumay
Maxay ahayd Astaamaha Bukaanka Qaaxada?
Ugu horreyntii, ciidanka Abbott ee PR iyo reersiyada daroogada ayaa soo baxay, iyagoo saxafiyiin saxafiyiin ah la socda saxafiyiinta iyo la xiriirka farmasiyada iyo dhakhaatiirta si ay u sii wadaan isku dayga inay ku sii wadaan synthroid, daroogada labaad ee daawada ugu badan ee Maraykanka, iyo halka laga helo $ 818 milyan iibinta sanadka 2003, sida "wanaagsan" levothyroxine.
Inkasta oo aanay jirin baadhitaan lagu sameeyo tan, FDA ayaa ku dhawaaqday daawooyinkan kala-duwanaanta ah, waxaa jiray xarun iibsi oo xoog leh si ay u riixdo, dukumiintiyada iyo farmashiyeyaasha loo soo bandhigo Synthroid isla markaana ka-dhigo farshaxanka. Farriintani, marka loo eego, ayaa sidoo kale lagu dhajiyay dhakhaatiir, oo u sheegay dadka bukaanka ah in "jilayaasha cusub aysan u wanaagsaneyn sida Synthroid."
Marka labaad, shirkadaha daroogada ayaa istaagay sheegashooyinka ah in mid ka mid ah uu ka fiican yahay mid kale ama markhaatiyadu ay ka fiican yihiin jilicsanaanta. Ilaa hadda, dib-u-eegida, dib-u-eegista, indho-indhoolayaasha indhoole ah ayaan weli la daabacin kuwaas oo isbarbardhigaya wax-ku-oolnimada iyo / ama ka sarreeya tayada gaar ahaaneed iyo calaamadaha, mana jirto caddayn in hal nooc oo levotokoxiin ka fiican yahay mid kale, ama Noocyada ma shaqeeyaan si siman iyo sidoo kale daroogada magaca daawada levothyroxine.
Saddexaad, shirkadaha caymiska iyo HMOs waxay beddeleen bukaanno badan oo u dhigma qiimaha hooseeya ee levothyroxine. Waxaa jira dad badan oo ku jira daroogooyinka kuwaas oo xitaa dhowr doolar oo kayd ah bil kasta, markii ay kordhiyeen kumanaan bukaan ah, waxay dhalisay in kaydka kharashka badan ee kooxahaasi ay doonayaan inay ku raaxaystaan.